Discover undervalued stocks with Eulerpool.

Subscribe for $2

I-Mab Stock IMAB

Price

0
Today +/-
-0
Today %
-0 %

I-Mab stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the I-Mab stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the I-Mab stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the I-Mab stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze I-Mab's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

I-Mab Stock Price History

DateI-Mab Price
10/7/20250 undefined
10/7/20254.31 undefined
10/6/20254.21 undefined
10/3/20254.41 undefined
10/3/20254.41 undefined
10/2/20254.10 undefined
10/1/20253.91 undefined
9/29/20253.78 undefined
9/28/20253.42 undefined
9/25/20253.48 undefined
9/24/20253.52 undefined
9/24/20253.71 undefined
9/24/20253.72 undefined
9/23/20253.89 undefined
9/22/20253.92 undefined
9/19/20253.84 undefined
9/19/20253.82 undefined
9/18/20253.71 undefined
9/17/20253.70 undefined
9/16/20253.73 undefined
9/15/20253.65 undefined
9/12/20254.01 undefined
9/11/20253.83 undefined
9/10/20254.12 undefined
9/9/20254.61 undefined
9/8/20254.31 undefined

I-Mab Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into I-Mab, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by I-Mab from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects I-Mab’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of I-Mab. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into I-Mab’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing I-Mab’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on I-Mab’s growth potential.

I-Mab Revenue, EBIT and net profit per share

DateI-Mab RevenueI-Mab EBITI-Mab Net Income
2030e111.72 M undefined0 undefined38.15 M undefined
2029e33.73 M undefined-48.8 M undefined-77.25 M undefined
2028e4.63 M undefined-61.18 M undefined-92.99 M undefined
2027e0 undefined-57.54 M undefined-89.65 M undefined
2026e0 undefined-46.51 M undefined-57.6 M undefined
2025e0 undefined-38.72 M undefined-31.47 M undefined
20240 undefined-51 M undefined-22 M undefined
202327.64 M undefined-49 M undefined-208 M undefined
2022-221.6 M undefined-1.97 B undefined-2.51 B undefined
202188 M undefined-2.07 B undefined-2.33 B undefined
20201.54 B undefined155.6 M undefined470.9 M undefined
201930 M undefined-1.47 B undefined-1.49 B undefined
201853.8 M undefined-438.6 M undefined-402.8 M undefined
201711.6 M undefined-281 M undefined-298.2 M undefined

I-Mab Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.010.050.031.540.09-0.220.03000000.030.11
-381.82-43.405,040.00-94.29-351.14-112.22-----725.00236.36
245.4550.9490.001.7546.59112.22100.00----675.0081.8224.32
000041-248270000000
-298-402-1,485470-2,331-2,507-208-22-31-57-89-92-7738
-34.90269.40-131.65-595.967.55-91.70-89.4240.9183.8756.143.37-16.30-149.35
131.2131.2131.2157.2174.7189.8191187000000
- - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The I-Mab Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the I-Mab is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (M)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (B)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (M)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (B)
TOTAL CAPITAL (B)
20172018201920202021202220232024
               
0.571.81.174.794.283.452.280.17
051.40357.9286.9000
3.85.729.585.189.58.200
000027.2000
113.7175.9162.3110.4101.3168.816.672.25
0.692.041.365.344.783.632.30.18
22.327.746.540.3158.51245.553.8
000664.8352.130.912.0831
00000000
148.8148.8148.8120.4119.7118.9118.110
162.6162.6162.6162.6162.6162.600
0018.3226.610.90.251.37
333.7339.1376.2990.1819.5447.3135.9936.17
1.032.381.746.335.64.072.440.21
               
0.712.923.100000
0.0500.397.79.19.581.481.46
-357.9-1,014.5-2,494.2-2,023.3-4,354.8-6,862.2-1,264-1,286
5.759.470.1-50.8-186.5213.84033
00000000
0.411.961.075.634.562.930.250.21
000057.40357.750
12.267.7264.2566.2564.3724.17.28.35
84198.5274.39.92.415.1510.11
998050001900
00000000
195.2346.2588.5576.1624.1758.2415.958.46
1146768.200000
00000000
02.511.4130.5417.6405.6683.07
11469.579.6130.5417.6405.6683.07
0.310.420.670.711.041.160.480.01
0.722.381.746.335.64.090.730.22
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of I-Mab provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand I-Mab's financial health and stability.

Assets

I-Mab's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that I-Mab must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of I-Mab after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into I-Mab's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (B)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (B)
CASH FLOW FROM FINANCING ACTIVITIES (B)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (B)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
201720182019202020212022
-298-402-1,452470-2,331-2,507
169141426
0000014
25147184-240394552
0.03-0.030.760.681.561.17
143100
000000
-252-280-868433-973-1,102
-20-14-12-8-29-45
-1579212-201-727458
-13723224-193-697504
000000
21040-30-50019
0.391.440.180.70.730.02
0.761.480.153.440.590.04
0.16002.79-0.140
000000
0.351.27-0.493.57-1.24-0.21
-272.5-295.1-880.2425.6-1,003-1,148.6
000000

I-Mab stock margins

The I-Mab margin analysis displays the gross margin, EBIT margin, as well as the profit margin of I-Mab. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for I-Mab.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the I-Mab's sales revenue. A higher gross margin percentage indicates that the I-Mab retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the I-Mab's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the I-Mab's total revenue generated. When comparing the revenue margin year over year, investors can gauge the I-Mab's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the I-Mab. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the I-Mab's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

I-Mab Margin History

I-Mab Gross marginI-Mab Profit marginI-Mab EBIT marginI-Mab Profit margin
2030e100 %0 %34.15 %
2029e100 %-144.7 %-229.06 %
2028e100 %-1,321.15 %-2,007.9 %
2027e100 %0 %0 %
2026e100 %0 %0 %
2025e100 %0 %0 %
2024100 %0 %0 %
2023100 %-177.25 %-752.42 %
2022112.27 %888.76 %1,131.45 %
202147.27 %-2,353.75 %-2,649.43 %
2020100 %10.09 %30.52 %
2019100 %-4,883.33 %-4,950 %
2018100 %-815.24 %-748.7 %
2017100 %-2,422.41 %-2,570.69 %

I-Mab Stock Sales Revenue, EBIT, Earnings per Share

The I-Mab earnings per share therefore indicates how much revenue I-Mab has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue I-Mab earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates I-Mab's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of I-Mab’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating I-Mab's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

I-Mab Revenue, EBIT and net profit per share

DateI-Mab Sales per ShareI-Mab EBIT per shareI-Mab Earnings per Share
2030e0.6 undefined0 undefined0.2 undefined
2029e0.18 undefined0 undefined-0.41 undefined
2028e0.02 undefined0 undefined-0.5 undefined
2027e0 undefined0 undefined-0.48 undefined
2026e0 undefined0 undefined-0.31 undefined
2025e0 undefined0 undefined-0.17 undefined
20240 undefined-0.27 undefined-0.12 undefined
20230.14 undefined-0.26 undefined-1.09 undefined
2022-1.17 undefined-10.38 undefined-13.21 undefined
20210.5 undefined-11.86 undefined-13.35 undefined
20209.81 undefined0.99 undefined3 undefined
20190.23 undefined-11.17 undefined-11.32 undefined
20180.41 undefined-3.34 undefined-3.07 undefined
20170.09 undefined-2.14 undefined-2.27 undefined

I-Mab business model

I-Mab is a Chinese biopharmaceutical company specializing in the development of innovative therapies for the treatment of cancer and autoimmune diseases. It was founded in 2016 by Dr. Jingwu Zang and is based in Shanghai, China. I-Mab's business model focuses on the development of antibody therapies tailored to the needs of cancer and autoimmune patients. They utilize the latest research and development to create therapies that address the unmet market demand. They work on cancer immunotherapy, including CAR-T cell therapy, and also on immunotherapy for autoimmune diseases, including rare ones. Their goal is to improve the lives of patients with cancer and autoimmune diseases through innovative biotechnology and research. They have promising products in development and clinical trials, such as AMG 228 and TJM2. They aim to make a significant contribution to healthcare with their dedicated team of researchers and scientists. I-Mab is one of the most popular companies on Eulerpool.com.

I-Mab SWOT Analysis

Strengths

1. Strong portfolio of innovative and potential breakthrough therapies in the biopharmaceutical industry.

2. Strategic partnerships and collaborative agreements with leading global pharmaceutical companies, enhancing research and development capabilities.

3. Established presence and reputation in the Chinese pharmaceutical market, a rapidly growing segment.

Weaknesses

1. Relatively small scale compared to larger pharmaceutical companies, limiting resources and competitive advantage.

2. High dependence on successful clinical trials and regulatory approvals, which pose significant risks to product development.

3. Limited global footprint beyond Chinese market, potentially impacting market reach and market penetration.

Opportunities

1. Growing global demand for innovative therapies presents opportunities for I-Mab to expand its market share outside of China.

2. Increasing government support and favorable policies in China encourage domestic biopharmaceutical companies like I-Mab to further invest in research and development.

3. Collaborative partnerships with academic institutions and research centers can provide access to additional expertise, resources, and potential breakthroughs.

Threats

1. Intense competition from both domestic and international pharmaceutical companies in the biopharmaceutical market.

2. Regulatory uncertainties and stringent approval processes in different markets may delay or hinder product commercialization.

3. Potential challenges in intellectual property protection and patent disputes may affect the company's ability to maximize the value of its innovations.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

I-Mab Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

I-Mab historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

I-Mab shares outstanding

The number of shares was I-Mab in 2024 — This indicates how many shares 187 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue I-Mab earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates I-Mab's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of I-Mab’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating I-Mab's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for I-Mab.

I-Mab latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2025-0.04 -0.07  (-61.76 %)2025 Q2
3/31/2025-0.07 -0.03  (54.75 %)2025 Q1
12/31/2024-0.06 -0.08  (-38.41 %)2024 Q4
9/30/2024-0.24 -0.25  (-5.62 %)2024 Q3
6/30/2024-1.33 -0.46  (65.36 %)2024 Q2
3/31/2024-0.22 -0.21  (6.25 %)2024 Q1
1

Eulerpool ESG Scorecard© for the I-Mab stock

Eulerpool World ESG Rating (EESG©)

27/ 100

🌱 Environment

12

👫 Social

46

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

I-Mab shareholders

%
Name
Stocks
Change
Date
8.47388 % Everest Medicines Ltd15,846,15015,846,1508/5/2025
6.39214 % CBC Group11,953,301-2,642,8578/5/2025
4.37007 % T Investment Ltd8,172,02203/19/2025
3.19816 % HHLR Advisors, Ltd.5,980,56806/30/2025
0.60565 % Candriam Belgium S.A.1,132,5631,132,5636/30/2025
0.60565 % Candriam Luxembourg S.A.1,132,5631,132,5636/30/2025
0.46864 % SG Americas Securities, L.L.C.876,35354,3126/30/2025
0.34551 % Zang (Jingwu Zhang)646,106100,3973/19/2025
0.17939 % Two Sigma Investments, LP335,466-238,1006/30/2025
0.15829 % Abaris Investment Management AG296,000-114,0006/30/2024
1
2
3
4
5
...
10

Most common questions regarding I-Mab

What values and corporate philosophy does I-Mab represent?

I-Mab is a biopharmaceutical company that is dedicated to discovering and developing innovative biologics to address unmet medical needs. Their corporate philosophy revolves around a patient-centric approach, focusing on improving patients' lives through advanced therapies. I-Mab values integrity, collaboration, and scientific excellence, aiming to provide breakthrough treatments for diseases with high unmet medical needs. With a strong commitment to delivering novel solutions, I-Mab continuously strives to be at the forefront of research and development in the biopharmaceutical industry.

In which countries and regions is I-Mab primarily present?

I-Mab is primarily present in China and the United States.

What significant milestones has the company I-Mab achieved?

I-Mab, a leading biopharmaceutical company, has achieved significant milestones throughout its journey. The company successfully conducted a Phase 3 clinical trial for its innovative therapy in treating diffuse large B-cell lymphoma, demonstrating its commitment to advancing healthcare solutions. Additionally, I-Mab received the U.S. FDA Fast Track Designation for its potential treatment of multiple myeloma, recognizing the company's dedication to developing breakthrough therapies. Furthermore, I-Mab forged strategic partnerships with renowned global pharmaceutical companies, reinforcing its position in the global market. Overall, I-Mab's achievements highlight its exceptional growth and commitment towards improving patients' lives through groundbreaking treatments.

What is the history and background of the company I-Mab?

I-Mab is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of cancer and autoimmune diseases. Founded in 2016, I-Mab focuses on the discovery and development of antibody-based drugs by leveraging its proprietary discovery and development platforms. This Chinese company has a strong emphasis on research and development, working on a diverse pipeline of potential drugs targeting various diseases. With a commitment to delivering novel and effective solutions, I-Mab has garnered recognition within the pharmaceutical industry for its innovative approach and dedication to improving patients' lives.

Who are the main competitors of I-Mab in the market?

The main competitors of I-Mab in the market include large biopharmaceutical companies such as Junshi Biosciences, Legend Biotech, BeiGene, and Innovent Biologics.

In which industries is I-Mab primarily active?

I-Mab is primarily active in the pharmaceutical industry.

What is the business model of I-Mab?

I-Mab is a clinical-stage biopharmaceutical company based in China. Its business model revolves around the discovery, development, and commercialization of innovative and differentiated biologics. I-Mab focuses on developing novel antibodies to address unmet medical needs in the fields of oncology, immuno-oncology, and autoimmune diseases. With a strong pipeline of potential therapies, I-Mab aims to bring groundbreaking treatments to patients globally. By advancing its drug candidates through rigorous research and strategic partnerships, I-Mab aims to revolutionize healthcare and improve patient outcomes.

What is the P/E ratio of I-Mab 2025?

The P/E ratio cannot be calculated for I-Mab at the moment.

What is the P/S ratio of I-Mab 2025?

The P/S cannot be calculated for I-Mab currently.

What is the Quality Investing of I-Mab?

The Quality Investing for I-Mab is 1/10.

What is the revenue of I-Mab 2025?

The revenue cannot currently be calculated for I-Mab.

How high is the profit of I-Mab 2025?

The expected I-Mab profit is -31.47 M USD.

What is the business model of I-Mab

I-Mab is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for serious diseases like cancer and immune disorders. They have a strong pipeline of products in the fields of oncology, autoimmune diseases, and cardiovascular diseases. They have partnerships with other companies to market their products worldwide. Overall, their business model is centered around developing and marketing effective therapies for challenging diseases and they have a unique partnership strategy.

What is the I-Mab dividend?

I-Mab pays a dividend of 0 USD distributed over payouts per year.

How often does I-Mab pay dividends?

The dividend cannot currently be calculated for I-Mab or the company does not pay out a dividend.

What is the I-Mab ISIN?

The ISIN of I-Mab is US44975P1030.

What is the I-Mab WKN?

The WKN of I-Mab is A2PVC6.

What is the I-Mab ticker?

The ticker of I-Mab is IMAB.

How much dividend does I-Mab pay?

Over the past 12 months, I-Mab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, I-Mab is expected to pay a dividend of 0 USD.

What is the dividend yield of I-Mab?

The current dividend yield of I-Mab is .

When does I-Mab pay dividends?

I-Mab pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of I-Mab?

I-Mab paid dividends every year for the past 0 years.

What is the dividend of I-Mab?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is I-Mab located?

I-Mab is assigned to the 'Health' sector.

Wann musste ich die Aktien von I-Mab kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of I-Mab from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.

When did I-Mab pay the last dividend?

The last dividend was paid out on 10/7/2025.

What was the dividend of I-Mab in the year 2024?

In the year 2024, I-Mab distributed 0 USD as dividends.

In which currency does I-Mab pay out the dividend?

The dividends of I-Mab are distributed in USD.

All fundamentals about I-Mab

Our stock analysis for I-Mab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of I-Mab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.